Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenalidomide + cyclophosphamide
- Development stage
- Discontinued
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lenalidomide + cyclophosphamide is a combination regimen that was evaluated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Lenalidomide is a small molecule immunomodulatory drug (IMiD) and thalidomide analogue that binds to cereblon, a component of the E3 ubiquitin ligase complex, resulting in the degradation of target proteins and subsequent antiangiogenic and antineoplastic effects. Cyclophosphamide is a nitrogen mustard alkylating agent that cross-links DNA, inhibiting DNA synthesis and cell division. A Phase I/II trial conducted by the University of Nebraska investigated the safety and efficacy of this combination, specifically evaluating its impact on prostate-specific antigen (PSA) levels and its ability to modulate the tumor microenvironment in hormone-refractory patients.
- Brand names
- Revlimid
- Other names
- lenalidomidecyclophosphamide
02
Targets
CRBN (Cereblon)DNA
Beyond the preview
Go deeper on lenalidomide + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenalidomide + cyclophosphamide.